- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
75 result(s) found for: Flushing.
Displaying page 1 of 4.
EudraCT Number: 2013-005083-26 | Sponsor Protocol Number: RD.03.SPR.40225E | Start Date*: 2014-02-28 | |||||||||||
Sponsor Name:Galderma R&D SNC | |||||||||||||
Full Title: Effect of CD07805/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea | |||||||||||||
Medical condition: Flushing related to erythematotelangiectatic or papulopustular rosacea | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003971-20 | Sponsor Protocol Number: ROS031019 | Start Date*: 2020-03-03 | |||||||||||
Sponsor Name:Rigshospitalet Glostrup | |||||||||||||
Full Title: An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea | |||||||||||||
Medical condition: Rosacea | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013620-22 | Sponsor Protocol Number: SOFISEP | Start Date*: 2009-10-07 |
Sponsor Name:AZIENDA SANITARIA LOCALE BI DI BIELLA | ||
Full Title: Multicenter randomized open clinical trial for `lock` efficacy assessment of totally implantable vascular access device with saline solution vs heparin | ||
Medical condition: Cancer patients with totally implantable vascular access device | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005093-70 | Sponsor Protocol Number: 0524A-020 | Start Date*: 2005-12-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme (Sweden) AB | |||||||||||||
Full Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercho... | |||||||||||||
Medical condition: Hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) AT (Completed) DE (Completed) ES (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002135-30 | Sponsor Protocol Number: NCT04379973 | Start Date*: 2021-04-28 |
Sponsor Name:Antwerp University Hospital (UZA) | ||
Full Title: Live birth after additional tubal flushing with oil-based contrast versus no additional flushing: a randomised, multicentre, parallel group pragmatic trial in infertile women with at least one pate... | ||
Medical condition: Infertility defined as lack of conception despite 12 months of unprotected intercourse, or three cycles of donor insemination without pregnancy or three ovulatory ovulation induction cycles without... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001895-40 | Sponsor Protocol Number: 109MS406 | Start Date*: 2014-05-02 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Te... | ||||||||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006393-29 | Sponsor Protocol Number: V00312 CA 201 | Start Date*: 2008-04-15 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT represented by Institut de Recherche Pierre Fabre | |||||||||||||
Full Title: A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) ... | |||||||||||||
Medical condition: Dyslipidemia with uncontrolled elevated triglycerides | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003856-30 | Sponsor Protocol Number: CSMS995ABE12T | Start Date*: 2016-01-28 |
Sponsor Name:Cliniques Universitaires Saint Luc | ||
Full Title: Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syn... | ||
Medical condition: The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreoti... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-004153-24 | Sponsor Protocol Number: NL62838.029.18 | Start Date*: 2019-07-30 |
Sponsor Name:Amsterdam UMC - location Vrije Universiteit Amsterdam | ||
Full Title: Tubal flushing with oil-based contrast during HSG in subfertile women: Is early flushing effective and cost-effective as compared to delayed flushing? | ||
Medical condition: The research population consists of infertile women aged between 18 and 39 years of age, who have a spontaneous menstrual cycle and with a perceived low risk for tubal pathology, undergoing fertili... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000739-25 | Sponsor Protocol Number: CSOM230C2303 | Start Date*: 2008-01-14 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately contr... | |||||||||||||
Medical condition: Metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FR (Completed) DE (Completed) IT (Prematurely Ended) ES (Prematurely Ended) GB (Completed) BE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016070-33 | Sponsor Protocol Number: 6913-004 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal W... | |||||||||||||
Medical condition: Vasomotor symptoms (hot flashes) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) BE (Completed) SE (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003107-39 | Sponsor Protocol Number: 0524A-023 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Merck & Co | |||||||||||||
Full Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001543-31 | Sponsor Protocol Number: LX1606.1-303-CS | Start Date*: 2014-02-17 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome | |||||||||||||
Medical condition: Carcinoid Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) SE (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001553-32 | Sponsor Protocol Number: MR/M024954/1 | Start Date*: 2015-10-09 | |||||||||||
Sponsor Name:Imperial College, Joint Research Compliance Office | |||||||||||||
Full Title: Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes | |||||||||||||
Medical condition: menopausal hot flushes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000661-16 | Sponsor Protocol Number: CGRP2020 | Start Date*: 2020-06-18 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet Glostrup | |||||||||||||||||||||||
Full Title: The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients | |||||||||||||||||||||||
Medical condition: Migraine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004429-34 | Sponsor Protocol Number: 2017.lipiodol.flush | Start Date*: 2018-02-15 | |||||||||||
Sponsor Name:UZ Brussel | |||||||||||||
Full Title: Histological and Transcriptional Changes caused by Endometrial Flushing with Lipiodol: A Cross Over Study. | |||||||||||||
Medical condition: Female subfertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002578-20 | Sponsor Protocol Number: ESN364_HF_204 | Start Date*: 2015-08-25 | |||||||||||
Sponsor Name:Euroscreen S.A | |||||||||||||
Full Title: Pilot/Phase IIa Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes | |||||||||||||
Medical condition: hot flashes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001091-40 | Sponsor Protocol Number: 2-47-52030-722 | Start Date*: 2004-09-22 |
Sponsor Name:Beaufour Ipsen Pharma | ||
Full Title: A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostati... | ||
Medical condition: Treatment of clinical symptoms of carcinoid syndrome. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001322-25 | Sponsor Protocol Number: A4291023 | Start Date*: 2006-07-20 | |||||||||||
Sponsor Name:Pfizer, S.A. | |||||||||||||
Full Title: A PHASE 2b MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPT... | |||||||||||||
Medical condition: Treatment of moderate to severe vasomotor symptoms (hot flushes) associated with menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016959-21 | Sponsor Protocol Number: BRN-2009-03 | Start Date*: 2010-02-19 | |||||||||||
Sponsor Name:LABORATOIRES BOIRON | |||||||||||||
Full Title: Etude contrôlée, randomisée en double aveugle versus placebo de l’efficacité de la spécialité homéopathique BRN-01 dans le traitement des bouffées de chaleur de la femme ménopausée | |||||||||||||
Medical condition: Bouffées de chaleur de la femme ménopausée | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
